Impact of glucose levels on advanced glycation end products in hemodialysis

Hemodialysis International

Volumn 11, Issue 3, 2007, Pages 278-285

  Godfrey, Amy Ruth ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

AGE; Diabetes; Hemodiafiltration; Hemodialysis; Hyperglycemia

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCOSE; OSMOTIC AGENT;

CHRONIC KIDNEY DISEASE; DIALYSIS MEMBRANE; DISEASE COURSE; HEMODIAFILTRATION; HEMODIALYSIS; HUMAN; HYPERGLYCEMIA; KIDNEY DONOR; KIDNEY FAILURE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PREDICTION; REVIEW; SURVIVAL RATE; WORLD HEALTH ORGANIZATION;

BLOOD GLUCOSE; CHRONIC DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMODIAFILTRATION; HUMANS; HYPERGLYCEMIA; KIDNEY FAILURE, CHRONIC;

EID: 34250777700     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2007.00180.x     Document Type: Review

References (57)

1. Satko SG, Freedman BI, Moossavi S. Genetic factors in end-stage renal disease. Kidney Int. 2005; 67 (Suppl): S46-S49.
2. United States Renal Data System (USRDS). Annual Data Report 2003.
3. Depner T. Hemodialysis adequacy: Basic essentials and practical points for the nephrologist in training. Hemodial Int. 2005; 9: 241-254.
4. United States Renal Data System (USRDS). Annual Data Report 2006.
5. Yavuz A, Tetta C, Ersoy FF, et al. Uremic toxins: A new focus on old subject. Semin Dial. 2005; 18: 203-211.
6. Vanholder RC, De Smet R. Pathophysiological effects of uremic retention solutes. J Am Soc Nephrol. 1999; 10: 1815-1823.
7. Vanholder RC, Ringoir SM. Adequacy of dialysis: A critical analysis. Kidney Int. 1992; 42: 540-558.
8. Dhondt A, Vanholder RC, Van Biesen W, Lameire N. The removal of uremic toxins. Kidney Int. 2000; 58 (Suppl): S47-S59.
9. Vanholder RC, De Smet R, Lameire N. Redesigning the map of uremic toxins. Contrib Nephrol. 2001; 133: 42-70.
10. Hörl WH. Are new toxins appearing on the horizon? Contrib Nephrol. 2001; 133: 28-41.
11. Canaud B, Bosc JY, Leray-Moragues H, et al. On-line hemodiafiltration: Safety and efficacy in long-term clinical practice. Nephrol Dial Transplant. 2000; 15(Suppl 1): S60-S67.
12. Kawanishi H. On-line hemodiafiltration in critical care. Ther Apher. 2002; 6: 199-203.
13. Bohlender JM, Franke S, Stein G, Wolf G. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol. 2005; 289: F645-F659.
14. Jakuš V, Rietbrock N. Advanced glycation end products and the progress of diabetic vascular complications. Physiol Res. 2004; 53: 131-142.
15. Henle T, Deppisch R, Beck W, Hergesell O, Hänsch GM, Ritz E. Advanced glycation end-products (AGE) during hemodialysis treatment: Discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant. 1999; 14: 1968-1975.
16. Lapolla A, Fedele D, Martano L, et al. Advanced glycation end products: A highly complex set of biologically relevant compounds detected by mass spectrometry. J Mass Spectrom. 2001; 36: 370-378.
17. Thomas MC, Forbes JM, MacIsaac R, Jermus G, Cooper ME. Low-molecular weight advanced glycation end products: Markers of tissue AGE accumulation and more? Ann NY Acad Sci. 2005; 1043: 644-654.
18. Palmer B. Dialysate composition in hemodialysis and peritoneal dialysis. Atlas Kidney Dis. 2000; 5: 2-2.8.
19. Forni LG, Hilton PJ. Continuous hemofiltration in the treatment of acute renal failure. N Engl J Med. 1997; 336: 1303-1309.
20. Mayfield J. Diagnosis and classification of diabetes mellitus: New criteria. Am Fam Physician. 1998; 58: 1355-1362, 1369-1370.
21. Parsons FM, Stewart WK. The Composition of Dialysis Fluid: Replacement of Renal Function by Dialysis. 2nd ed. Boston: Martinus-Nijhoff. 1983: 148-170.
22. Sam R, Vaseemuddin M, Leong WH, Rogers BE, Kjellstrand CM, Ing TS. Composition and clinical use of hemodialysates. Hemodial Int. 2006; 10: 15-28.
23. Styszynski A, Podkowka R, Wieczorowska-obis K, et al. Glucose suppresses peritoneal inflammatory reactions and mesothelial hyperplasia caused by intraperitoneal saline infusion. Adv Perit Dial. 2002; 18: 21-25.
24. Le Poole CY, van Ittersum FJ, Weijmer MC, Valentijn RM, ter Wee PM. Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: A randomized crossover study. Adv Perit Dial. 2004; 20: 170-176.
25. Dawnay AB, Millar DJ. Glycation and advanced glycation end-product formation with icodextrin and dextrose. Perit Dial Int. 1997; 17: 52-58.
26. Faller B. Amino acid-based peritoneal dialysis solutions. Kidney Int. 1996; 56(Suppl): S81-S85.
27. Miyata T, Horie K, Ueda Y, et al. Advanced glycation and lipidoxidation of the peritoneal membrane: Respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int. 2000; 58: 425-435.
28. Heaton A, Ward MK, Johnston DG, Nicholson DV, Alberti KG, Kerr D. Short-term studies on the use of glycerol as an osmotic agent in continuous ambulatory peritoneal dialysis. Clin Sci. 1984; 67: 121-130.
29. Smit W, de Waart DR, Struijk DG, Krediet RT. Peritoneal transport characteristics with glycerol-based dialysate in peritoneal dialysis. Perit Dial Int. 2000; 20: 557-565.
30. DeFronzo RA. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerosis. Neth J Med. 1997; 50: 191-197.
31. Rao G. Insulin resistance syndrome. Am Fam Physician. 2001; 63: 1159-1163.
32. Bressler P, Bailey SR, Matsuda M, DeFronzo RA. Insulin resistance and coronary artery disease. Diabetologia. 1996; 39: 1345-1350.
33. Rhodes CJ. Type 2 diabetes: A matter of β-cell life and death? Science. 2005; 307: 380-383.
34. Dukic-Stefanovic S, Schinzel R, Riederer P, Münch G. AGES in brain aging: AGE-inhibitors as neuroprotective and anti-dementia drugs. Biogerontology. 2001; 2: 19-34.
35. ε-(carboxymethyl)lysine] in Alzheimer's disease brains. Acta Neuropathol. 2001; 101: 27-35.
36. Schultz Johansen J, Harris AK, Rychly DJ, Ergul A. Oxidative stress and the use of antioxidants in diabetes: Linking basic science to clinical practice. Cardiovasc Diabetol. 2005; 4.
37. Way KJ, Katai N, King GL. Protein kinase C and the development of diabetic vascular complications. Diabet Med. 2001; 18: 945-959.
38. Hayden MR, Sowers JR, Tyagi SC. The central role of extracellular matrix and basement membrane remodelling in metabolic syndrome and type 2 diabetes: The matrix preloaded. Cardiovasc Diabetol. 2005; 4.
39. Peppa M, Uribarri J, Vlassara H. Glucose, advanced glycation end products, and diabetes complications: What is new and what works. Clin Diabetes. 2003; 21: 186-187.
40. Lin KY, Ito A, Asagami T, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation. 2002; 106: 987-992.
41. Umans JG, Levi R. Nitric oxide in the regulation of blood flow and arterial pressure. Annu Rev Physiol. 1995; 57: 771-790.
42. Channon KM, Qian H, George SE. Nitric oxide synthase in atherosclerosis and vascular injury. Arterioscl Thromb Vasc Biol. 2000; 20: 1873-1881.
43. Baynes JW, Thorpe SR. Glycoxidation and lipidoxidation in atherogenesis. Free Radic Biol Med. 2000; 28: 1708-1716.
44. Miyata T, Ishiguro N, Yasuda Y, et al. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem Biophys Res Commun. 1998; 244: 45-49.
45. Šebekova K, Kupèová V, Schinzel R, Heidland A. Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis-amelioration by liver transplantation. J Hepatol. 2002; 36: 66-71.
46. Yamamoto Y, Sakata N, Meng J, et al. Possible involvement of increased glycoxidation and lipid peroxidation of elastin in atherogenesis in haemodialysis patients. Nephrol Dial Transplant. 2002; 17: 630-636.
47. Do ate T, Herreros A, Martinez E, et al. Protein oxidative stress in dialysis patients. Adv Perit Dial. 2002; 18: 15-17.
48. Miyata T, Akhand AA, Kurokawa K, Nakashima I. Reactive carbonyl compounds as uremic toxins. Contrib Nephrol. 2001; 133: 71-80.
49. Suliman ME, Heimburger O, Barany P, et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol. 2003; 14: 1614-1622.
50. Losing a Million Minds: Confronting the Tragedy of Alzheimer's Disease and Other Dementias. U.S. Congress Office of Technology Assessment; U.S. Government Printing Office; 1987, p. 14.
51. Corbett M, Dalton S, Young A, Silman A, Shipley M. Factors predicting death, survival and functional outcome in a prospective study of early rheumatoid disease over fifteen years. British J Rheumatol. 1993; 32: 717-723.
52. National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health. Age-adjusted death rates of liver cirrhosis by sex: Death registration States, 1910-1932, and United States, 1933-2003.
53. Forbes JM, Teo Loon Yee L, Thallas V, et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes. 2004; 53: 1813-1823.
54. Friedman EA. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications. Diabetes Care. 1999; 22: B65-B71.
55. Williams ME. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease. Curr Diab Rep. 2004; 4: 441-446.
56. Friedlander MA, Ching Wu Y, Elgawish A, Monnier VM. Early and advanced glycosylation end products: Kinetics of formation and clearance in peritoneal dialysis. J Clin Invest. 1996; 97: 728-735.
57. Henle T, Schwenger V, Ritz E. Preliminary studies on the renal handling of lactuloselysine from milk products. Czech J Food Sci. 2000; 18: S101-S102.